A Two-Year Double-masked, Randomized, Sham-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Ultevursen in Subjects with Retinitis Pigmentosa (RP) due to Mutations in Exon 13 of the USH2A Gene
Research Grant
Awarded By
Ora, Inc.
Start Date
September 16, 2024
End Date
January 31, 2028
Awarded By
Ora, Inc.
Start Date
September 16, 2024
End Date
January 31, 2028